(Reuters) – U.S. health regulators on Friday approved an oral treatment from Roche and PTC Therapeutics for spinal muscular atrophy, in adults and children two months of age and older.
The drug, risdiplam, will be sold under the brand name Evrysdi and compete with Biogen’s Spinraza, the first medicine approved for the leading genetic cause of death in infants, and Novartis’ gene therapy Zolgensma.
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Shailesh Kuber)
